LONDON – Research and health emerged as the biggest losers following a marathon four days of negotiations by EU leaders on the bloc’s €1.1 trillion (US$1.3 trillion) 2021 - 2027 budget and the formation of a €750 billion (US$872 billion) pandemic recovery fund. Rather than €94.4 billion over the next seven years as proposed, the R&D program Horizon Europe, will get €80.9 billion. Read More
Four IPOs from biopharmas chasing an aggregate $781.8 million launched on Friday with mixed results. Two of the companies, Inozyme Pharma Inc. and Annexon Inc., finished the day in positive territory while the other two, Iteos Therapeutics Inc. and Nurix Therapeutics Inc., saw their shares close flat. Read More
DUBLIN – Although Europe has moved first to approve Blenrep (belantamab mafodotin), Glaxosmithkline plc’s antibody-drug conjugate (ADC) as a fifth-line therapy in relapsed or refractory multiple myeloma, U.S. patients may well be first to gain access to the new drug. Read More
With no new cases reported for more than 100 days, Taiwan appears to have successfully contained the spread of COVID-19 and has drawn attention to its medical achievements. Experts said at BIO Asia-Taiwan conference this week that with continuous government and investor support, the East Asian nation could move further up to join other leading biotech players. Read More
The FDA approved Kite Pharma Inc.’s Tecartus (brexucabtagene autoleucel, KTE-X19), the first cell-based gene therapy for adults with mantle cell lymphoma (MCL) who have not responded to or who have relapsed following other kinds of treatment. Read More
HONG KONG – Tokyo-based Daiichi Sankyo Co. Ltd. has hit its goals in a phase III study testing the use of prasugrel hydrochloride in thrombotic stroke patients. Read More
BioWorld looks at translational medicine, including: Structural study gives insight into plaque formation; Studying labor identifies new pain mechanism; AHR inhibition suppresses Zika infection; iPSCs find best therapy for Best disease. Read More
The top two biggest money biopharma deals in 2020 occurred in June, putting the month ahead of all other months for the year in terms of deal values and volumes. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alector, Amgen, Chi-Med, Cytomx, Northwest, Noxxon, Polarityte, Theratechnologies, UCB. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aptorum, Arcturus, Cel-Sci, Fujifilm, Hansoh, Menarini, Novavax, Protalix, Radius, Sarcomed, Sareum, Sorrento, Smartpharm, Tissue Regenix. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adaptimmune, Astrazeneca, Biomarin, Blueprint, Galapagos, Gilead, Heron, Insmed, Kyowa Kirin, Miragen, Myokardia, Novartis, Oncoceutics, Sarepta, Vistagen. Read More
